TCGA-98-A538-01A-11R-A262-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.620
- G2M_CHECKPOINT+0.580
- E2F_TARGETS+0.570
- MYC_TARGETS_V1+0.500
- MTORC1_SIGNALING+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.400
- MITOTIC_SPINDLE+0.380
- OXIDATIVE_PHOSPHORYLATION+0.380
- PI3K_AKT_MTOR_SIGNALING+0.370
- DNA_REPAIR+0.310
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.380
- ANGIOGENESIS-0.350
- COAGULATION-0.340
- PANCREAS_BETA_CELLS-0.340
- COMPLEMENT-0.290
- INTERFERON_GAMMA_RESPONSE-0.270
- ALLOGRAFT_REJECTION-0.260
- IL6_JAK_STAT3_SIGNALING-0.260
- MYOGENESIS-0.260
- INFLAMMATORY_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8392891 | — | cohortSQ2 | 0.916 |
| 2 | TCGA-18-5595-01A-01R-1635-07 | — | cohortSQ2 | 0.912 |
| 3 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.905 |
| 4 | TCGA-60-2722-01A-01R-0851-07 | — | cohortSQ2 | 0.905 |
| 5 | TCGA-66-2792-01A-01R-0980-07 | — | cohortSQ2 | 0.904 |
| 6 | SRR8392895 | — | cohortSQ2 | 0.895 |
| 7 | TCGA-33-4538-01A-01R-1201-07 | — | cohortSQ2 | 0.891 |
| 8 | TCGA-94-7557-01A-11R-2125-07 | — | cohortMD1 | 0.891 |
| 9 | MDT-AP-2030 | Med | Medulloblastoma | 0.882 |
| 10 | TCGA-68-7755-01A-11R-2125-07 | — | cohortSQ2 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.580 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.210 | Remibrutinib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.140 | Idelalisib | — uncovered |